MedTrace Logo

A Study of CLR325 in Chronic Stable Heart Failure Patients.

NCT02696967 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.

Conditions

  • Chronic Stable Heart Failure

Interventions

DRUG

CLR325

CLR325 Concentrate for solution for infusion

OTHER

Placebo

Normal saline

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-17
Primary Completion
2019-01-14
Completion
2019-01-14
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Germany
  • Netherlands
  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02696967 on ClinicalTrials.gov